Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 4/20 | 0.45 |
| ▸ | ATP4B | P51164 | 4/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.39 |
| ▸ | BRS3 | P32247 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6459040 | 0.94 | ATP4A (0.45) | ATP4AATP4BPDE10ABRS3KDM4E | |
| SCHEMBL9784698 | 0.92 | PDE10A (0.38) | ATP4AATP4BPDE10ABRS3ALDH1A1 | |
| SCHEMBL6883696 | 0.86 | ATP4A (0.50) | ATP4AATP4B | |
| SCHEMBL6882120 | 0.85 | ATP4A (0.62) | ATP4AATP4BPDE10A | |
| SCHEMBL6883713 | 0.85 | ATP4A (0.55) | ATP4AATP4BPDE10A | |
| SCHEMBL6881365 | 0.83 | ATP4A (0.47) | ATP4AATP4BPDE10ABRS3KDM4E | |
| SCHEMBL10368704 | 0.82 | ATP4A (0.46) | ATP4AATP4BPDE10ABRS3KDM4E | |
| SCHEMBL10843919 | 0.82 | PDE10A (0.42) | PDE10ABRS3KDM4EALDH1A1 | |
| SCHEMBL6881355 | 0.81 | ATP4A (0.51) | ATP4AATP4BPDE10A | |
| SCHEMBL10714254 | 0.81 | PDE10A (0.36) | ATP4AATP4BPDE10ABRS3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| EP-0166287-B1 | DIALKOXYRIDINES, PROCESS FOR THEIR PREPARATION, THEIR APPLICATION AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1989-08-23 | — | — | EP | disclosed |
| US-4758579-A | e.g. pantoprazole or pantoprazole sodium | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0166287-A1 | Dialkoxyridines, process for their preparation, their application and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | ATP4A 298/4885ATP4B 428/4885PDE10A 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.